Search

Your search keyword '"Den Boer, M. L."' showing total 306 results
Start Over Author "Den Boer, M. L."
306 results on '"Den Boer, M. L."'

1. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study

Author

Boer, J M, van der Veer, A, Rizopoulos, D, Fiocco, M, Sonneveld, E, de Groot-Kruseman, H A, Kuiper, R P, Hoogerbrugge, P, Horstmann, M, Zaliova, M, Palmi, C, Trka, J, Fronkova, E, Emerenciano, M, do Socorro Pombo-de-Oliveira, M, Mlynarski, W, Szczepanski, T, Nebral, K, Attarbaschi, A, Venn, N, Sutton, R, Schwab, C J, Enshaei, A, Vora, A, Stanulla, M, Schrappe, M, Cazzaniga, G, Conter, V, Zimmermann, M, Moorman, A V, Pieters, R, and den Boer, M L

Published
2016
Full Text
View/download PDF

6. miR-9 is a tumor suppressor in pediatric AML with t(8;21)

Author

Emmrich, S, Katsman-Kuipers, J E, Henke, K, Khatib, M E, Jammal, R, Engeland, F, Dasci, F, Zwaan, C M, den Boer, M L, Verboon, L, Stary, J, Baruchel, A, de Haas, V, Danen-van Oorschot, A A, Fornerod, M, Pieters, R, Reinhardt, D, Klusmann, J H, and van den Heuvel-Eibrink, M M

Published
2014
Full Text
View/download PDF

10. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Author

Brivio, E., Locatelli, Franco, Lopez-Yurda, M., Malone, A., Diaz-de-Heredia, C., Bielorai, B., Rossig, C., van der Velden, V. H. J., Ammerlaan, A. C. J., Thano, A., van der Sluis, I. M., den Boer, M. L., Chen, Y., Sleight, B., Brethon, B., Nysom, K., Sramkova, L., Ora, I., Vinti, L., Chen-Santel, C., Zwaan, C. M., Locatelli F. (ORCID:0000-0002-7976-3654), Brivio, E., Locatelli, Franco, Lopez-Yurda, M., Malone, A., Diaz-de-Heredia, C., Bielorai, B., Rossig, C., van der Velden, V. H. J., Ammerlaan, A. C. J., Thano, A., van der Sluis, I. M., den Boer, M. L., Chen, Y., Sleight, B., Brethon, B., Nysom, K., Sramkova, L., Ora, I., Vinti, L., Chen-Santel, C., Zwaan, C. M., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple relapsed/refractory (R/R) CD22+ acute lymphoblastic leukemia (ALL). Patients (age ≥1 year or <18 years) received 3 doses of InO (days 1, 8, and 15) per course. Dose escalation was based on dose-limiting toxicities (DLTs) during course 1. Dose level 1 (DL1) was 1.4 mg/m2 (0.6, 0.4, 0.4 mg/m2) and DL2 was 1.8 mg/m2 (0.8, 0.5, 0.5 mg/m2). Secondary end points included safety, antileukemic activity, and pharmacokinetics. Twenty-five patients (23 evaluable for DLTs) were enrolled. In course 1, the first cohort had 1 of 6 (DL1) and 2 of 5 (DL2) patients who experienced DLTs; subsequent review considered DL2 DLTs to be non–dose-limiting. Dose was de-escalated to DL1 while awaiting protocol amendment to re-evaluate DL2 in a second cohort, in which 0 of 6 (DL1) and 1 of 6 (DL2) patients had a DLT. Twenty-three patients experienced grade 3 to 4 adverse events; hepatic sinusoidal obstruction syndrome was reported in 2 patients after subsequent chemotherapy. Overall response rate after course 1 was 80% (95% confidence interval [CI], 59% to 93%) (20 of 25 patients; DL1: 75% [95% CI, 43% to 95%], DL2: 85% [95% CI, 55% to 98%]). Of the responders, 84% (95% CI, 60% to 97%) achieved minimal residual disease (MRD)-negative complete response, and 12-month overall survival was 40% (95% CI, 25% to 66%). Nine patients received hematopoietic stem cell transplantation or chimeric antigen receptor T cells after InO. InO median maximum concentrations were comparable to simulated adult concentrations. InO was well tolerated, demonstrating antileukemic activity in heavily pretreated children with CD22+ R/R ALL. RP2D was established as 1.8 mg/m2 per course, as in adults. This trial was registered at https://www.clinicaltrialsregister.eu as EUDRA-CT 2016-000227-71. Key Points: • The recommended phase 2 dose of InO for

Published
2021

11. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study

Author

Boer, J, Valsecchi, M, Hormann, F, Antic, Z, Zaliova, M, Schwab, C, Cazzaniga, G, Arfeuille, C, Cave, H, Attarbaschi, A, Strehl, S, Escherich, G, Imamura, T, Ohki, K, Gruber, T, Sutton, R, Pastorczak, A, Lammens, T, Lambert, F, Li, C, Carrillo de Santa Pau, E, Hoffmann, S, Moricke, A, Harrison, C, Den Boer, M, De Lorenzo, P, Stam, R, Bergmann, A, Pieters, R, Boer J. M., Valsecchi M. G., Hormann F. M., Antic Z., Zaliova M., Schwab C., Cazzaniga G., Arfeuille C., Cave H., Attarbaschi A., Strehl S., Escherich G., Imamura T., Ohki K., Gruber T. A., Sutton R., Pastorczak A., Lammens T., Lambert F., Li C. K., Carrillo de Santa Pau E., Hoffmann S., Moricke A., Harrison C. J., Den Boer M. L., De Lorenzo P., Stam R. W., Bergmann A. K., Pieters R., Boer, J, Valsecchi, M, Hormann, F, Antic, Z, Zaliova, M, Schwab, C, Cazzaniga, G, Arfeuille, C, Cave, H, Attarbaschi, A, Strehl, S, Escherich, G, Imamura, T, Ohki, K, Gruber, T, Sutton, R, Pastorczak, A, Lammens, T, Lambert, F, Li, C, Carrillo de Santa Pau, E, Hoffmann, S, Moricke, A, Harrison, C, Den Boer, M, De Lorenzo, P, Stam, R, Bergmann, A, Pieters, R, Boer J. M., Valsecchi M. G., Hormann F. M., Antic Z., Zaliova M., Schwab C., Cazzaniga G., Arfeuille C., Cave H., Attarbaschi A., Strehl S., Escherich G., Imamura T., Ohki K., Gruber T. A., Sutton R., Pastorczak A., Lammens T., Lambert F., Li C. K., Carrillo de Santa Pau E., Hoffmann S., Moricke A., Harrison C. J., Den Boer M. L., De Lorenzo P., Stam R. W., Bergmann A. K., and Pieters R.

Published
2021

12. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study

Author

den Boer, M, Cario, G, Moorman, A, Boer, J, de Groot-Kruseman, H, Fiocco, M, Escherich, G, Imamura, T, Yeoh, A, Sutton, R, Dalla-Pozza, L, Kiyokawa, N, Schrappe, M, Roberts, K, Mullighan, C, Hunger, S, Vora, A, Attarbaschi, A, Zaliova, M, Elitzur, S, Cazzaniga, G, Biondi, A, Loh, M, Pieters, R, den Boer M. L., Cario G., Moorman A. V., Boer J. M., de Groot-Kruseman H. A., Fiocco M., Escherich G., Imamura T., Yeoh A., Sutton R., Dalla-Pozza L., Kiyokawa N., Schrappe M., Roberts K. G., Mullighan C. G., Hunger S. P., Vora A., Attarbaschi A., Zaliova M., Elitzur S., Cazzaniga G., Biondi A., Loh M. L., Pieters R., den Boer, M, Cario, G, Moorman, A, Boer, J, de Groot-Kruseman, H, Fiocco, M, Escherich, G, Imamura, T, Yeoh, A, Sutton, R, Dalla-Pozza, L, Kiyokawa, N, Schrappe, M, Roberts, K, Mullighan, C, Hunger, S, Vora, A, Attarbaschi, A, Zaliova, M, Elitzur, S, Cazzaniga, G, Biondi, A, Loh, M, Pieters, R, den Boer M. L., Cario G., Moorman A. V., Boer J. M., de Groot-Kruseman H. A., Fiocco M., Escherich G., Imamura T., Yeoh A., Sutton R., Dalla-Pozza L., Kiyokawa N., Schrappe M., Roberts K. G., Mullighan C. G., Hunger S. P., Vora A., Attarbaschi A., Zaliova M., Elitzur S., Cazzaniga G., Biondi A., Loh M. L., and Pieters R.

Abstract

Background: ABL-class fusion genes other than BCR–ABL1 have been identified in approximately 3% of children with newly diagnosed acute lymphocytic leukaemia, and studies suggest that leukaemic cells carrying ABL-class fusions can be targeted successfully by tyrosine-kinase inhibitors. We aimed to establish the baseline characteristics and outcomes of paediatric patients with ABL-class fusion B-cell acute lymphocytic leukaemia in the pre-tyrosine-kinase inhibitor era. Methods: This multicentre, retrospective, cohort study included paediatric patients (aged 1–18 years) with newly diagnosed ABL-class fusion (ABL1 fusion-positive, ABL2 fusion-positive, CSF1R fusion-positive, and PDGFRB fusion-positive) B-cell acute lymphocytic leukaemia enrolled in clinical trials of multidrug chemotherapy done between Oct 3, 2000, and Aug 28, 2018, in which tyrosine-kinase inhibitors had not been given as a first-line treatment. Patients from 14 European, North American, and Asia-Pacific study groups of the Ponte di Legno group were included. No patients were excluded, and patients were followed up by individual study groups. Through the Ponte di Legno group, we collected data on the baseline characteristics of patients, including IKZF1, PAX5, and CDKN2A/B deletion status, and whether haematopoietic stem cell transplantation (HSCT) had been done, as well as treatment outcomes, including complete remission, no response, relapse, early death, and treatment-related mortality, response to prednisone, and minimal residual disease (MRD) at end of induction therapy. 5-year event-free survival and 5-year overall survival were estimated by use of Kaplan-Meier methods, and the 5-year cumulative incidence of relapse was calculated by use of a competing risk model. Findings: We identified 122 paediatric patients with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukaemia (77 from European study groups, 25 from North American study groups, and 20 from Asia-Pacific study groups). 64 (52

Published
2021

25. The MLL recombinome of acute leukemias

Author

Meyer, C, Schneider, B, Jakob, S, Strehl, S, Attarbaschi, A, Schnittger, S, Schoch, C, Jansen, M W J C, van Dongen, J J M, den Boer, M L, Pieters, R, Ennas, M-G, Angelucci, E, Koehl, U, Greil, J, Griesinger, F, zur Stadt, U, Eckert, C, Szczepański, T, Niggli, F K, Schäfer, B W, Kempski, H, Brady, H J M, Zuna, J, Trka, J, Nigro, L L, Biondi, A, Delabesse, E, Macintyre, E, Stanulla, M, Schrappe, M, Haas, O A, Burmeister, T, Dingermann, T, Klingebiel, T, and Marschalek, R

Published
2006
Full Text
View/download PDF

49. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Author

Jerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M.P., Boer, J. M., Besselink, N. J.M., Boeree, A., Van De Ven, C., De Groot-Kruseman, H. A., De Haas, V., Horstmann, M. A., Escherich, G., Zwaan, C. M., Cuppen, E., Koudijs, M. J., Pieters, R., Den Boer, M. L., Jerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M.P., Boer, J. M., Besselink, N. J.M., Boeree, A., Van De Ven, C., De Groot-Kruseman, H. A., De Haas, V., Horstmann, M. A., Escherich, G., Zwaan, C. M., Cuppen, E., Koudijs, M. J., Pieters, R., and Den Boer, M. L.

Published
2018

50. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Author

Lab Reumatologie/Klinische Immunologie, Other research (not in main researchprogram), PMC Medisch specialisten, CMM, Genetica Sectie Genoomdiagnostiek, Child Health, Jerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M.P., Boer, J. M., Besselink, N. J.M., Boeree, A., Van De Ven, C., De Groot-Kruseman, H. A., De Haas, V., Horstmann, M. A., Escherich, G., Zwaan, C. M., Cuppen, E., Koudijs, M. J., Pieters, R., Den Boer, M. L., Lab Reumatologie/Klinische Immunologie, Other research (not in main researchprogram), PMC Medisch specialisten, CMM, Genetica Sectie Genoomdiagnostiek, Child Health, Jerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M.P., Boer, J. M., Besselink, N. J.M., Boeree, A., Van De Ven, C., De Groot-Kruseman, H. A., De Haas, V., Horstmann, M. A., Escherich, G., Zwaan, C. M., Cuppen, E., Koudijs, M. J., Pieters, R., and Den Boer, M. L.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results